Yang
88 IP cases indexed. Covers patent matters.
Cases Presided Over
88 cases indexed | Page 2 of 3
Nike, Inc. v.SherryWear, LLC
Nike successfully petitioned the PTAB to challenge SherryWear's apparel patent, leading the Board to institute proceedings on obviousness grounds. The decision focuses on whether combinations of prior art references teach or suggest the claimed design elements in intimate apparel.
Nike, Inc. v.SherryWear, LLC et al.
Nike successfully petitioned to challenge SherryWear's bra design patent (9808036) on grounds of obviousness over combinations of prior art references. The PTAB institution decision found that Nike had established a reasonable likelihood of prevailing on the asserted claims, leading to trial.
Nike, Inc. v.SherryWear, LLC
Nike successfully petitioned to challenge key claims of SherryWear's intimate apparel patent (9723878) on grounds of obviousness. The PTAB instituted review, finding a reasonable likelihood that at least one claim is unpatentable over combinations of prior art like Vidal/Spagna and Handras/Spagna.
Nike, Inc. v.SherryWear, LLC
Nike successfully secured institution for all 14 claims of SherryWear's patent, overcoming the Patent Owner's attempt at discretionary denial. The Board found that Nike presented a reasonable likelihood of prevailing on Claim 1 over Barg and Pintor, leading to an IPR trial.
Nike, Inc. v.SherryWear, LLC
Nike successfully petitioned to challenge seven claims of SherryWear's patent based on obviousness over prior art references including Spagna and Rose. The Board found a reasonable likelihood of success regarding claim 1, leading to the institution of the IPR.
DR. FALK PHARMA GMBH v.Ellodi Pharmaceuticals LP
DR. FALK PHARMA GMBH challenged Ellodi Pharmaceuticals LP's '729 patent, asserting obviousness of claims related to orally disintegrating corticosteroids for GI tract inflammation. The PTAB declined to deny the petition, finding that additional evidence warranted reconsideration of prior art references like Dohil and FDA Guidance.
Illumina, Inc. v.Molecular Loop Biosciences, Inc.
Illumina successfully petitioned the PTAB to institute trial against Molecular Loop Biosciences' patent claims related to genomic sequencing and analysis. The Board found a reasonable likelihood of prevailing on at least claim 1, allowing the IPR to proceed despite extensive prior art challenges under Sections 102 and 103.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies successfully petitioned IPR against Tecan Genomics' NGS patent (US 10036012), showing a reasonable likelihood that prior art (Meyer) anticipates claims. The Board granted institution, setting the stage for a full trial on all 22 challenged claims.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies successfully challenged the '108 patent's claims in a PTAB institution decision, finding reasonable likelihood of prevailing on anticipation for Claim 1. The Board affirmed that prior art disclosure was sufficient to support the enrichment limitation using Meyer et al.
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully convinced the PTAB to institute trial proceedings against Tecan Genomics, Inc. regarding a high-throughput sequencing patent (11098357). The Board found reasonable likelihood that claims 1 through 10 are unpatentable under both anticipation (§ 102) and obviousness (§ 103).
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully petitioned to institute IPR proceedings against Tecan Genomics for patent number 11725241. The Board found sufficient evidence of unpatentability across multiple claims based on grounds of anticipation (35 U.S.C. § 102) and obviousness (35 U.S.C. § 103).
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully petitioned the PTAB against Tecan Genomics regarding claims related to Next-Generation Sequencing (NGS). The Board instituted review, finding a reasonable likelihood of prevailing on obviousness grounds.
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully petitioned to institute IPR proceedings against Tecan Genomics, challenging claims of U.S. Patent No. 10876108 based on obviousness (35 U.S.C. § 103). The Board found that the Examiner erred in relying solely on secondary considerations, adopting the Petitioner's view that combining Shapero and Delseny renders multiple claims obvious.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully secured the institution of Inter Partes Review against Ellodi Pharmaceuticals LP's patent (10632069). The review challenges claims 1-17 based on obviousness over prior art, including Dohil and FDA guidance.
Dr. Falk Pharma GMBH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully petitioned to institute IPR against Ellodi Pharmaceuticals LP's patent (11,246,828) over orally disintegrating tablet claims. The Board found a reasonable likelihood of success based on prior art showing obviousness.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully secured the institution of IPR against Ellodi Pharmaceuticals LP regarding patent 9,486,407. The Board found a reasonable likelihood that prior art (Dohil) renders Claim 35 obvious.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully challenged a pharmaceutical patent (11260061) in an IPR, showing a reasonable likelihood of prevailing on grounds of obviousness (§ 103). The Board's decision hinged on extensive claim construction, particularly defining 'adsorbed onto a pharmaceutically acceptable carrier.'
Berkshire Hathaway Energy Company et al. v.MES, Inc.
The PTAB institution decision found a reasonable likelihood of prevailing for the Petitioners regarding claims covering flue gas pollutant removal. The Board addressed both anticipation and obviousness grounds, concluding that the combination of prior art references was sufficiently motivated to render the asserted claims unpatentable.
Berkshire Hathaway Energy Company et al. v.MES, Inc.
Berkshire Hathaway Energy et al. successfully petitioned to institute IPR against Birchtech Corp.'s patent (10668430) covering mercury removal from flue gas. The Board found Petitioners established a reasonable likelihood of prevailing on grounds of obviousness and anticipation.
PacifiCorp et al. v.MES, Inc.
The PTAB granted institution for an IPR challenging claims related to mercury removal from flue gas using activated carbon sorbents. The Board found the Petitioner met a reasonable likelihood of prevailing standard, despite disputes over prior art reduction to practice.
PacifiCorp et al. v.MES, Inc.
The Board instituted the IPR petition against Patent No. 10589225, finding a reasonable likelihood of prevailing on multiple grounds. The institution decision addressed complex issues regarding real party in interest and written description support for genus claims related to flue gas treatment.
Xencor, Inc. v.Merus N.V.
Xencor, Inc. successfully petitioned the PTAB to institute an IPR against Merus N.V.'s patent (9358286) concerning heterodimeric Ig-like molecules. The Board found sufficient evidence of unpatentability under 35 U.S.C. §§ 102 and 103, advancing the dispute into the substantive review phase.
Xencor, Inc. v.Merus N.V.
Xencor, Inc. successfully petitioned to institute IPR against Merus N.V.'s patent (11926859) covering heterodimeric antibodies. The Board found reasonable likelihood of unpatentability based on written description and obviousness grounds.
PacifiCorp et al. v.MES, Inc.
The PTAB institution decision found that the Petitioner successfully established a reasonable likelihood of prevailing on multiple claims against Birchtech Corp.'s patent. The grounds for unpatentability centered on obviousness (103) based on combining prior art related to pollutant removal from flue gas.
PacifiCorp et al. v.MES, Inc.
PacifiCorp successfully challenged 26 claims of Birchtech Corp.'s patent (10926218) related to flue gas desulfurization, leading the PTAB to find a reasonable likelihood of prevailing on at least one claim. The Board concluded that combining prior art references was an obvious application of known techniques in mercury removal technology.
PacifiCorp et al. v.MES, Inc.
PacifiCorp et al. successfully convinced the PTAB to institute IPR proceedings against MES, Inc.'s patent (10926218) regarding pollutant removal from flue gas. The Board found a reasonable likelihood of prevailing on both anticipation and obviousness grounds based on multiple prior art references.
PacifiCorp et al. v.MES, Inc.
The PTAB denied institution of an IPR for a mercury removal patent (10926218) after the Director remanded the case due to multiple concurrent petitions. The denial was based on following the Director's instruction to prioritize one petition over another.
Inari Agriculture, Inc. v.Pioneer Hi-Bred International, Inc.
The PTAB denied institution of a PGR petition challenging the patentability of an inbred maize variety, finding that the petitioner failed to meet the burden of showing unpatentability on merits. The Board specifically noted the lack of evidence regarding the claimed genotype and found no unsettled legal questions warranting institutional review.
NeoGenomics Laboratories, Inc. v.Natera, Inc.
NeoGenomics filed an IPR challenging Natera's prenatal‑testing patent. The parties settled before the Board could institute the trial, and the Board granted a joint motion to terminate the proceeding.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies sought IPR of Tecan Genomics' patent covering nucleic acid technologies. The patent owner filed a terminal disclaimer of the entire patent, prompting the Board to grant an adverse judgment and terminate the proceeding.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.